SANA

#2366
Sana Biotechnology, Inc. - Common Stock
3.8 8 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.84
3.89
Intervallo Annuale
2.61
6.55
Variazione giornaliera
-1.02%
Variazione Mensile
+12.79%
Variazione di 6 mesi
0.00%
Variazione Annuale
+30.64%
Chiusura Precedente
3.9 2
Open
3.8 5
Minimo
3.8 4
Massimo
3.8 9
Volume
284
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Sana Biotechnology, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Sana Biotechnology, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Sana Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Sana Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Sana Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Sana Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Sana Biotechnology, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Sana Biotechnology, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Sana Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Sana Biotechnology, Inc. current report, Q1 FY2026
8-K

Sana Biotechnology, Inc. current report, Q1 FY2026

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Sana Biotechnology, Inc. on February 17, 2026. The filing discloses the appointment of a new Chief Financial Officer and the transition of the Principal Financial Officer role.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and personnel changes.

Material Changes

  • Executive Appointment: Brian Piper, M.B.A., was appointed as Executive Vice President, Chief Financial Officer, and Treasurer, effective February 17, 2026.
  • Role Transition: Steven D. Harr, M.D., ceased serving as acting Principal Financial Officer immediately prior to Mr. Piper's commencement date.
  • Compensation Package:
    • Annual base salary: $515,000.
    • Target annual bonus: 40% of base salary.
    • Equity grant: 900,000 stock options (vesting 25% on first anniversary, then monthly) and 200,000 restricted stock units (vesting annually over four years).
  • Severance Terms: In the event of termination without cause or resignation for good reason (outside of a change in control window), Mr. Piper is eligible for nine months of base salary and continued health coverage.

Guidance, Outlook, and Risks

The filing does not provide financial guidance, operational outlook, or discuss specific business risks. It notes that Mr. Piper has no family relationships with directors or officers and no undisclosed transactions requiring disclosure under Item 404(a) of Regulation S-K.

Key Facts for Investor Verification

  • Verify the vesting schedule and exercise price of the 900,000 stock options granted to the new CFO.
  • Review the full text of the Offer Letter (Exhibit 10.1) for specific definitions of "cause," "good reason," and "change in control."
  • Confirm the impact of the leadership transition on the company's financial reporting timeline and internal controls.
  • Check the 2025 Proxy Statement referenced in the filing for details on the Change in Control Severance Plan.

Notizie